Skip to main content

SYSTEMATIC REVIEW article

Front. Pain Res.
Sec. Cancer Pain
Volume 5 - 2024 | doi: 10.3389/fpain.2024.1512925

Comprehensive Evaluation of Compound Kushen injection Combined with Zoledronic Acid in Treating Bone Metastasis Cancer Pain Based on Meta-Analysis and Decision Tree Model

Provisionally accepted
Xi Zhao Xi Zhao 1Tianwei Meng Tianwei Meng 2xi yan xi yan 1kaiqiang wang kaiqiang wang 3Yuqiang Liu Yuqiang Liu 1Xinghua Li Xinghua Li 1*
  • 1 Changzhi People's Hospital, Changzhi, Shanxi Province, China
  • 2 Heilongjiang University of Chinese Medicine, Harbin, China
  • 3 Changzhi Medical College, Changzhi, Shanxi Province, China

The final, formatted version of the article will be published soon.

    To evaluate the safety, efficacy, and cost-effectiveness of combining Compound Kushen Injection (CKI) with zoledronic acid in the treatment of bone metastasis-induced cancer pain in malignant tumors.A comprehensive search of Chinese and English databases identified randomized controlled trials (RCTs) investigating CKI combined with zoledronic acid for bone metastases in malignancies. Methodological quality assessments were performed on all included studies, and a meta-analysis was conducted using RevMan 5.4.1 software. A cost-effectiveness analysis from the perspective of China's healthcare system employed a decision tree model to evaluate the short-term economic impact of the two treatment regimens. Sensitivity analyses assessed the robustness of the results.Results: Fourteen studies involving 1,269 patients were included in the meta-analysis. The results demonstrated that CKI combined with zoledronic acid was more effective than zoledronic acid alone in treating bone metastatic cancer pain (OR = 3.43, 95% CI: 2.51-4.67, P < 0.0001), with no significant difference in adverse reactions between the two groups. Incremental cost-effectiveness ratio (ICER) analysis revealed that the combination therapy incurred an additional cost of ¥18,863.16 for each unit of effect gained compared to zoledronic acid alone. Sensitivity analyses indicated stable results, showing that under the assumption of a willingness-to-pay threshold set at the average per capita disposable income in 2023, the combination of CKI and zoledronic acid was more cost-effective than zoledronic acid alone in treating bone metastatic cancer pain.Compared with zoledronic acid alone, the combination of CKI and zoledronic acid offers superior efficacy, high safety, and better cost-effectiveness in the treatment of bone metastasis-induced cancer pain in malignant tumors.

    Keywords: Meta-analysis, decision tree, Compound kushen injection, Zoledronic Acid, bone metastasis

    Received: 17 Oct 2024; Accepted: 30 Dec 2024.

    Copyright: © 2024 Zhao, Meng, yan, wang, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xinghua Li, Changzhi People's Hospital, Changzhi, Shanxi Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.